Abstract
Induction of apoptosis in cancer cells with chemotherapy and radiation treatment is a major strategy in cancer therapy at present. Nevertheless, innate or acquired resistance has been an obstacle for conventional clinical therapy. TNF-related apoptosis inducing ligand (TRAIL / Apo-2L) is a typical member of the TNF ligand family that induces apoptosis through activating the death receptors. In recent years, considerable attention has been focused on the potential benefits of TRAIL in cancer therapy, as the majority of cancer cells are sensitive to TRAIL-induced apoptosis, while most normal cells are TRAIL-resistant. Furthermore, the use of TRAIL in combination with chemotherapeutic agents or irradiation strengthens its apoptotic effects. In this review, we will discuss the regulation mechanism of TRAIL-induced apoptosis and the molecular basis of the synergies created by its use in combination with chemotherapeutic agents and irradiation. We also analyze in detail that TRAIL may be cytotoxic, as this is a potential obstacle to its development for being used in cancer therapy.
Keywords: trail, cancer therapy, tnf-related apoptosis inducing ligand, tnf ligand family, death receptors, trail-resistant
Current Molecular Medicine
Title: TRAIL: A Potential Agent for Cancer Therapy
Volume: 3 Issue: 8
Author(s): Juan Shi, Dexian Zheng, Kwan Man, Sheung-tat Fan and Ruian Xu
Affiliation:
Keywords: trail, cancer therapy, tnf-related apoptosis inducing ligand, tnf ligand family, death receptors, trail-resistant
Abstract: Induction of apoptosis in cancer cells with chemotherapy and radiation treatment is a major strategy in cancer therapy at present. Nevertheless, innate or acquired resistance has been an obstacle for conventional clinical therapy. TNF-related apoptosis inducing ligand (TRAIL / Apo-2L) is a typical member of the TNF ligand family that induces apoptosis through activating the death receptors. In recent years, considerable attention has been focused on the potential benefits of TRAIL in cancer therapy, as the majority of cancer cells are sensitive to TRAIL-induced apoptosis, while most normal cells are TRAIL-resistant. Furthermore, the use of TRAIL in combination with chemotherapeutic agents or irradiation strengthens its apoptotic effects. In this review, we will discuss the regulation mechanism of TRAIL-induced apoptosis and the molecular basis of the synergies created by its use in combination with chemotherapeutic agents and irradiation. We also analyze in detail that TRAIL may be cytotoxic, as this is a potential obstacle to its development for being used in cancer therapy.
Export Options
About this article
Cite this article as:
Shi Juan, Zheng Dexian, Man Kwan, Fan Sheung-tat and Xu Ruian, TRAIL: A Potential Agent for Cancer Therapy, Current Molecular Medicine 2003; 3 (8) . https://dx.doi.org/10.2174/1566524033479401
DOI https://dx.doi.org/10.2174/1566524033479401 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
Call for Papers in Thematic Issues
Molecular and Cellular Mechanisms in Vertigo / Vestibular Disorders
Vertigo and vestibular diseases are common among middle-aged and older adults, significantly increasing the risk of falls and leading to injuries and disabilities. Despite their prevalence, therapeutic advancements are hindered by a limited understanding of the underlying molecular and cellular mechanisms. This Special Issue is dedicated to bridging this gap ...read more
Related Journals

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pro-apoptotic Activity of BH3-only Proteins and BH3 Mimetics: from Theory to Potential Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry microRNAs in Cancer: Lessons from Melanoma
Current Pharmaceutical Design Radioguided Surgery for Localization of Nonpalpable Breast Lesions A Mini-Review
Current Radiopharmaceuticals Vaccine Ingredients: Components that Influence Vaccine Efficacy
Mini-Reviews in Medicinal Chemistry Emerging Evidence for Neurotensin Receptor 1 Antagonists as Novel Pharmaceutics in Neurodegenerative Disorders
Mini-Reviews in Medicinal Chemistry Novel Oral Anticoagulants: Recommendations for Patient Evaluation, Treatment Initiation, Follow-up and Perioperative Management
Cardiovascular & Hematological Disorders-Drug Targets Bone Target Radiotracers for Palliative Therapy of Bone Metastases
Current Medicinal Chemistry Gene Therapy for Gastric Diseases
Current Gene Therapy Importance and Limitations of Chemotherapy Among the Available Treatments for Gastrointestinal Tumours
Anti-Cancer Agents in Medicinal Chemistry Neurorestorative Role of Stem Cells in Alzheimer’s Disease: Astrocyte Involvement
Current Alzheimer Research Attenuation of ERK/RSK2-Driven NFκB Gene Expression and Cancer Cell Proliferation by Kurarinone, a Lavandulyl Flavanone Isolated from Sophora flavescens Ait. Roots
Endocrine, Metabolic & Immune Disorders - Drug Targets An Overview on Global Trends in Nanotechnological Approaches for Alzheimer Therapy
Current Drug Metabolism From ONYX-015 to Armed Vaccinia Viruses: The Education and Evolution of Oncolytic Virus Development
Current Cancer Drug Targets Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry Telomerase Inhibitors: Potential Anticancer Agents
Mini-Reviews in Organic Chemistry Research Progress in Flavonoids as Potential Anticancer Drug Including Synergy with Other Approaches
Current Topics in Medicinal Chemistry Using Bioinformatics Techniques for Gene Identification in Drug Discovery and Development
Current Drug Metabolism Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Nanoinformatics and Personalized Medicine: An Advanced Cumulative Approach for Cancer Management
Current Medicinal Chemistry Melanin-Concentrating Hormone as a Metabolic and Cognitive Regulatory Factor
Current Medicinal Chemistry - Central Nervous System Agents